Miller Mary has filed 28 insider transactions across 1 company since September 2023.
Most recent transaction: a grant/award of 129760 shares of Acrivon Therapeutics, Inc. ($ACRV) on March 01, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | A | Stock Option (Right to Buy) | 129760 | $0.00 | 129,760.0000 | 38,560,464 | 9999.99% | 0.34% |
| Feb. 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 217 | $1.63 | 33,679.0000 | 38,560,464 | 0.64% | 0.00% |
| Jan. 17, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 659 | $1.98 | 33,896.0000 | 38,560,464 | 1.91% | 0.00% |
| Nov. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 184 | $2.24 | 34,555.0000 | 38,560,464 | 0.53% | 0.00% |
| Oct. 17, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 558 | $1.81 | 34,739.0000 | 38,560,464 | 1.58% | 0.00% |
| Oct. 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 284 | $1.81 | 35,297.0000 | 38,560,464 | 0.80% | 0.00% |
| Aug. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 184 | $1.39 | 35,581.0000 | 33,791,817 | 0.51% | 0.00% |
| July 17, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 558 | $1.32 | 35,765.0000 | 33,791,817 | 1.54% | 0.00% |
| May 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 184 | $1.14 | 36,323.0000 | 33,791,817 | 0.50% | 0.00% |
| April 17, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 558 | $1.81 | 36,507.0000 | 33,791,817 | 1.51% | 0.00% |
| April 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | A | Stock Option (Right to Buy) | 15616 | $0.00 | 15,616.0000 | 33,791,817 | 9999.99% | 0.05% |
| March 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | A | Stock Option (Right to Buy) | 93693 | $0.00 | 93,693.0000 | 33,791,817 | 9999.99% | 0.28% |
| Feb. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 217 | $5.42 | 37,065.0000 | 33,791,817 | 0.58% | 0.00% |
| Jan. 17, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 659 | $5.78 | 37,282.0000 | 33,791,817 | 1.74% | 0.00% |
| March 1, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | A | Stock Option (Right to Buy) | 67567 | $0.00 | 67,567.0000 | 22,078,190 | 9999.99% | 0.31% |
| Nov. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 184 | $7.92 | 37,941.0000 | 38,105,131 | 0.48% | 0.00% |
| Oct. 17, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 558 | $7.87 | 38,125.0000 | 38,105,131 | 1.44% | 0.00% |
| Oct. 1, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 284 | $6.98 | 38,683.0000 | 38,105,131 | 0.73% | 0.00% |
| Aug. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 184 | $7.02 | 38,967.0000 | 22,078,190 | 0.47% | 0.00% |
| July 17, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 558 | $7.69 | 39,151.0000 | 22,078,190 | 1.41% | 0.00% |
| May 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 184 | $8.36 | 39,709.0000 | 22,078,190 | 0.46% | 0.00% |
| April 17, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 558 | $10.34 | 39,893.0000 | 22,078,190 | 1.38% | 0.00% |
| Feb. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 217 | $3.40 | 40,451.0000 | 22,078,190 | 0.53% | 0.00% |
| Jan. 17, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 652 | $4.35 | 40,668.0000 | 22,078,190 | 1.58% | 0.00% |
| Nov. 14, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 735 | $5.08 | 41,320.0000 | 0 | 1.75% | 0.00% |
| Oct. 17, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | F | Common Stock | 2232 | $5.48 | 42,055.0000 | 0 | 5.04% | 0.00% |
| Sept. 26, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | A | Stock Option (Right to Buy) | 11576 | $0.00 | 11,576.0000 | 0 | 9999.99% | 0.00% |
| Sept. 26, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Miller Mary | Chief Legal Officer | A | Common Stock | 3858 | $0.00 | 44,287.0000 | 0 | 9.54% | 0.00% |